公开(公告)号：US20170101460A1

公开(公告)日：2017-04-13

申请号：US15110555

申请日：2015-01-12

申请人： ALLERMABS CO. LTD.

发明人： Alfur Fu-Hsin Hung ,  Donic Chien-Sheng Lu ,  Tse-Wen Chang

IPC分类号： C07K16/00 ,  C12N5/16 ,  C12N5/26 ,  A01K67/027

CPC分类号： C07K16/00 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  C07K2317/24 ,  C07K2317/52 ,  C12N5/163 ,  C12N5/166 ,  C12N2510/02

摘要： The transgenic non-human animals are constructed, in whose genome the coding sequences of one of the animal's endogenous immunoglobulin Cγ constant regions are replaced by human immunoglobulin Cε constant region coding sequences. The transgenic animal is mouse, in whose genome the Cγ1 constant regions are replaced by the human immunoglobulin Cε constant regions and the Cκ constant region is replaced by the human immunoglobulin Cκ constant region. The transgenic mouse yields humanized IgE-secreting B cells and antigen-specific humanized IgE after immunization. The transgenic animals are employed to prepare serum containing humanized IgE, antiserum containing antigen-specific humanized IgE, and monoclonal antigen-specific humanized IgE antibodies by hybridoma and other technologies.

公开(公告)号：US20160376561A1

公开(公告)日：2016-12-29

申请号：US15263257

申请日：2016-09-12

申请人： Bell Biosystems, Inc.

发明人： Caleb Bell, III ,  Alexey Bazarov

IPC分类号： C12N5/26 ,  C12N9/88 ,  C12N15/03 ,  C12Q1/68

CPC分类号： C12N5/166 ,  C12N1/00 ,  C12N5/00 ,  C12N5/16 ,  C12N9/88 ,  C12N15/02 ,  C12N15/03 ,  C12Q1/6897 ,  C12Y406/01001

摘要： The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.

公开(公告)号：US20150210985A1

公开(公告)日：2015-07-30

申请号：US14684252

申请日：2015-04-10

申请人： Thiru Venkat Gopal

发明人： Thiru Venkat Gopal

IPC分类号： C12N5/26

CPC分类号： C12N5/0619 ,  C12N5/0691 ,  C12N5/16 ,  C12N5/166 ,  C12N2500/46 ,  C12N2501/06 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/59 ,  C12N2501/73 ,  C12N2501/998 ,  C12N2506/00 ,  C12N2506/30

摘要： Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated human cancer cell. Methods to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment of a human patient by administering the patient-specific cell line to the patient.

摘要翻译： 公开哺乳动物细胞质供体细胞系。 患者特异性细胞系的披露。 通过融合分化的哺乳动物细胞和功能去核的哺乳动物胚胎细胞系获得哺乳动物细胞质供体细胞系的方法。 通过融合分化的哺乳动物细胞和功能去核的人类癌细胞获得哺乳动物细胞质供体细胞系的方法。 通过功能性去除哺乳动物细胞质供体细胞系并将功能性去核的哺乳动物细胞质供体细胞系与从患者获得的分化细胞融合来获得类似于哺乳动物细胞质供体细胞系的细胞类型的患者特异性细胞系的方法。 一种通过向患者施用患者特异性细胞系来治疗人类患者的方法。

公开(公告)号：US20120052569A1

公开(公告)日：2012-03-01

申请号：US13265024

申请日：2010-04-21

申请人： Junichi Takagi

发明人： Junichi Takagi

IPC分类号： C07K7/06 ,  C12N15/11 ,  C07K4/00 ,  C07K16/44 ,  C12N5/26 ,  C12S99/00 ,  C07K19/00 ,  C12N15/63

CPC分类号： C07K16/10 ,  A61K47/65 ,  C07K1/22 ,  C07K7/06 ,  C07K2317/34 ,  C07K2317/92 ,  C07K2319/40 ,  C07K2319/50 ,  C12P21/06

摘要： Provided is a tag peptide in which a protease recognition sequence and an epitope of an antibody against the tag peptide are overlapped and thereby the protease recognition sequence per se is usable for detection or purification. Also provided is a purification method for recombinant proteins using the tag peptide and an antibody thereagainst. A preferable tag peptide comprises a Tobacco etch virus (TEV) protease recognition sequence as the protease recognition sequence, and its examples include a tag peptide comprising the amino acid sequence (1): RX1X2LYX3QGKDG (wherein X1, X2 and X3 may be the same or different and represent any amino acid residue).

摘要翻译： 提供了一种标签肽，其中蛋白酶识别序列和针对标签肽的抗体的表位重叠，从而蛋白酶识别序列本身可用于检测或纯化。 还提供了使用标签肽和抗体的重组蛋白质的纯化方法。 优选的标签肽包括作为蛋白酶识别序列的烟草蚀刻病毒（TEV）蛋白酶识别序列，其实例包括包含氨基酸序列（1）的标签肽：RX1X2LYX3QGKDG（其中X1，X2和X3可以相同或 不同，代表任何氨基酸残基）。

公开(公告)号：US20120034690A1

公开(公告)日：2012-02-09

申请号：US12802801

申请日：2010-06-15

申请人： Dirk M. Anderson

发明人： Dirk M. Anderson

IPC分类号： C12N5/18 ,  C12N5/26

CPC分类号： C07K16/241 ,  A61K38/00 ,  C07K14/435 ,  C07K14/52 ,  C07K14/525 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/7151 ,  C07K16/2875 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/73 ,  C12Q1/6876

摘要： Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.

摘要翻译： 本文描述了用于制备结合RANKL的抗体的细胞系和方法，包括产生人RANKL阻断抗体的细胞系。

公开(公告)号：US07220559B2

公开(公告)日：2007-05-22

申请号：US09767578

申请日：2001-01-23

申请人： Ilya Trakht

发明人： Ilya Trakht

IPC分类号： C12N15/07 ,  C12N5/22 ,  C12N5/24 ,  C12N5/26 ,  C12N5/28

CPC分类号： C07K16/3069 ,  C07K16/1235 ,  C07K16/2863 ,  C07K16/3015 ,  C07K2317/21 ,  C12N5/163 ,  C12N5/166 ,  C12N2510/02 ,  C12N2510/04 ,  G01N33/56983 ,  G01N33/57484 ,  G01N33/6893 ,  Y10S530/808 ,  Y10S530/809

摘要： This invention provides: a heteromyeloma, other than B6B11, capable of producing a trioma when fused with a human lymphoid cell, wherein the trioma is capable of producing a monoclonal antibody-secreting tetroma when fused with a second, antibody-secreting human lymphoid cell; a trioma fusion partner which does not produce antibody, obtained by fusing a heteromyeloma which does not produce antibody with a human lymphoid cell; a monoclonal antibody-secreting tetroma, obtained by fusing a trioma which does not produce antibody with an antibody-secreting human lymphoid cell; a method of producing a monoclonal antibody that specifically recognizes an antigen associated with a condition; a method of identifying an antigen associated with a condition using the trioma fusion partner; a method of diagnosing a condition using the trioma fusion partner; a method for preventing a condition; and compositions and therapeutic compositions comprising monoclonal antibodies produced using the trioma fusion partner.

摘要翻译： 本发明提供：当与人类淋巴样细胞融合时能够产生三胞胎的B6B11以外的异源骨髓瘤，其中当与第二种抗体分泌型人类淋巴样细胞融合时，三瘤能够产生单克隆抗体分泌性四唑; 通过将不产生抗体的异源骨髓瘤与人类淋巴样细胞融合得到的不产生抗体的三瘤融合伴侣; 通过将不产生抗体的三血症与抗体分泌型人淋巴样细胞融合获得的单克隆抗体分泌性四唑; 一种产生特异性识别与病症有关的抗原的单克隆抗体的方法; 使用三聚体融合配偶体鉴定与病症相关的抗原的方法; 使用三聚体融合伴侣诊断病症的方法; 一种预防病症的方法; 以及包含使用三聚体融合配偶体产生的单克隆抗体的组合物和治疗组合物。

公开(公告)号：US07041499B2

公开(公告)日：2006-05-09

申请号：US10021741

申请日：2001-12-12

申请人： Porunellor A. Mathew ,  Kent Boles

发明人： Porunellor A. Mathew ,  Kent Boles

IPC分类号： C12N5/16 ,  C12N5/26 ,  C07K16/28

CPC分类号： C07K16/2806 ,  A61K2039/505 ,  C07K14/70507 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/30

摘要： The present invention relates to nucleic acid molecules encoding cell surface receptors on immune cells and the characteristic peptides that comprise these receptors. More specifically, the present invention concerns the use of synthetic and recombinant peptides comprising natural killer (“NK”) cell surface receptors. The synthetic and recombinant peptides are used to generate monoclonal antibodies that bind a specific NK cell surface receptor called CS1. The binding of the monoclonal antibody to the NK cell surface receptor leads to NK cell activation. In a particular embodiments of the present invention, the monoclonal antibodies are utilized in a method that inhibits the growth of tumor cells.

公开(公告)号：US5635376A

公开(公告)日：1997-06-03

申请号：US235276

申请日：1994-04-29

申请人： Andrew P. Feinberg ,  Jae-Yong Lee

发明人： Andrew P. Feinberg ,  Jae-Yong Lee

IPC分类号： C12N5/077 ,  C12N15/10 ,  C12P19/34 ,  C12N5/10 ,  C12N5/26 ,  C12N15/64

CPC分类号： C12N15/1003 ,  C12N2510/04

摘要： Introducing a chromosome or chromosome fragment having a size of 25 to 500 Mb and containing a selectable marker into a female muntjac cell which has been immortalized with a nonviral vector, a chemical treatment, or a radiation treatment permits the easy purification of the chromosome or chromosome fragment.

摘要翻译： 将具有25-500Mb大小的染色体或染色体片段引入到用非病毒载体，化学处理或放射治疗进行永生化的雌性ac ac细胞中，可以容易地纯化染色体或染色体 分段。

公开(公告)号：US5472868A

公开(公告)日：1995-12-05

申请号：US230432

申请日：1994-04-19

申请人： Robert T. McCormack ,  Ru-shya Liu ,  Joseph V. Manetta ,  John R. Sportsman

发明人： Robert T. McCormack ,  Ru-shya Liu ,  Joseph V. Manetta ,  John R. Sportsman

IPC分类号： C12N5/10 ,  C07K16/00 ,  C12N5/26 ,  C12N15/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/577 ,  C12N5/20

CPC分类号： C12N5/166 ,  C07K16/00

摘要： A stable xenogeneic fusion partner that is a product of the fusion of a mouse myeloma cell and a non-transformed rabbit partner cell. The fusion partner produces undetectable levels of antibody, as determined by an enzyme linked immunosorbent assay. A method for generating rabbit monoclonal antibodies is disclosed that comprises fusing a nontransformed rabbit partner cell with a rodent myeloma cell to produce a xenogeneic fusion partner, selecting a stable fusion partner producing undetectable levels of antibodies, fusing the stable fusion partner with a rabbit antibody producing cell and isolating an antibody producing cell line that produces antibodies directed to a predetermined antigen.

摘要翻译： 稳定的异种融合伴侣，其是小鼠骨髓瘤细胞和非转化的兔配偶体细胞融合的产物。 融合配偶体通过酶联免疫吸附测定法测定，产生不可检测的抗体水平。 公开了产生兔单克隆抗体的方法，其包括将非转化的兔配偶体细胞与啮齿动物骨髓瘤细胞融合以产生异种融合伴侣，选择产生不可检测水平的抗体的稳定融合配偶体，将稳定融合配偶体与产生兔抗体融合 分离产生针对预定抗原的抗体的产生抗体的细胞系。

公开(公告)号：US11419316B2

公开(公告)日：2022-08-23

申请号：US16189603

申请日：2018-11-13

申请人： ABS Global, Inc.

发明人： Jon Lightner ,  Richard Williams

IPC分类号： A01K67/027 ,  A61D19/02 ,  A61K35/52 ,  A61K35/54 ,  A61D19/00 ,  C12N5/12 ,  C12N5/26 ,  C12N5/073 ,  A01K67/02 ,  A61D19/04

摘要： Systems for selecting, generating, and breeding hybrid dairy cattle are described, as are methods for maintaining herds of hybrid cattle.